We describe the case of a young child with multidrug-resistant tuberculosis, treated with linezolid. The child developed severe neutropenia after 5 months of treatment. Filgrastim was used, a drug that officially is not indicated for non-cytostatic drug-induced neutropenia. This allowed the fast recovery of the patient's neutrophil-count. However, more experience with the off-label use of filgrastrim is needed in the pediatric population.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724981 | PMC |
| http://dx.doi.org/10.1007/s11096-013-9814-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Population Pharmacokinetic-Pharmacodynamic Modeling of Granulocyte Colony-Stimulating Factor to Optimize Dosing and Timing for CD34 Cell Harvesting.
Clin Transl Sci
January 2025
Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea.
Granulocyte colony-stimulating factor (G-CSF) mobilizes peripheral blood (PB) progenitor cells from bone marrow (BM) into circulation for PB stem cell transplantation (PBSCT). This study aimed to develop a population pharmacokinetic-pharmacodynamic (PK-PD) model of filgrastim in healthy subjects to optimize PB CD34 cell collection. Plasma filgrastim concentrations and CD34 cell count data were obtained from a clinical study involving healthy Korean subjects.
View Article and Find Full Text PDFFactors influencing white blood cell mobilisation in healthy granulocyte donors.
Transfus Med
November 2024
Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Article Synopsis
- Granulocyte transfusions are used for patients with severe neutropenia and infections resistant to standard treatments, with higher granulocyte doses leading to better outcomes.
- A study analyzed data from 312 granulocyte collections to determine how donor characteristics like age, gender, and baseline blood counts affect the efficiency of granulocyte mobilization.
- Results showed younger donors had better mobilization efficiency, with female donors having higher platelet counts while the donor's age was negatively correlated with mobilization efficiency.
[Investigation of the Changes in Blood Cell Components following the Administration of Pegfilgrastim in Neo-Adjuvant and Adjuvant FEC Chemotherapy for Breast Cancer].
Gan To Kagaku Ryoho
September 2024
Dept. of Pharmacy, The Cancer Institute Hospital.
Article Synopsis
- Perioperative FEC therapy is a common treatment for breast cancer, but over 20% of patients experience febrile neutropenia (FN), which pegfilgrastim is often used to prevent.
- A study on pegfilgrastim's long-term safety found no significant differences in blood cell counts or long-term effects after one year of use.
- Pegfilgrastim administration significantly reduced the incidence of FN (6.5% with pegfilgrastim vs. 22.8% without), indicating it can be safely used for one year in breast cancer patients undergoing chemotherapy.
Demonstration of physicochemical and functional similarity between Stimufend (pegfilgrastim-fpgk) and Neulasta (pegfilgrastim): A comparative analytical assessment.
PLoS One
October 2024
Fresenius Kabi SwissBioSim GmbH, Eysins, Switzerland.
Background: Pegfilgrastim is a long-acting recombinant human granulocyte colony-stimulating factor biologic that is indicated to reduce the incidence of infections, manifested by febrile neutropenia, in patients receiving myelosuppressive anti-cancer drugs and to increase survival in patients acutely exposed to myelosuppressive doses of radiation. Due to the high cost of biologic therapy and the scarcity of biosimilar alternatives, there is an unmet medical need for targeted biologics.
Objective: This comparative analytical investigation aimed to confirm the similarity of biosimilar Stimufend® (pegfilgrastim-fpgk) to reference product Neulasta® (pegfilgrastim).
Enhancing patient-centered care: a randomized study on G-CSF administration preferences in chemotherapy-induced neutropenia.
Support Care Cancer
October 2024
Rafael Institute, Integrative Medicine Center, Levallois-Perret, France.
Article Synopsis
- The study aimed to compare patient preferences for administering pegfilgrastim, a medication used to prevent chemotherapy-induced neutropenia, via prefilled syringe versus pen device among cancer patients at the Rafael Institute in France.
- In the trial involving 150 patients, results showed a significant preference for the pen device, with participants reporting lower pain levels and more positive emotions compared to the syringe, although satisfaction with nursing care was higher with the syringe.
- Overall, the findings highlighted a stronger preference for using the pen device for administration, which can help shape clinical practices and enhance patient-centered care.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!